ThromboGenics Appoints Emmanuèle Attout as Independent Non-Executive Director
January 22, 2015 04:00 ET
|
Oxurion NV
Leuven, Belgium - 22 January, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines,...
ThromboGenics Appoints Dominique Vanfleteren as new Chief Financial Officer
January 07, 2015 08:00 ET
|
Oxurion NV
Leuven, Belgium - 7 January, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, is...
ThromboGenics' Commitment to the US Retina Community Highlighted at American Association of Ophthalmology 2014 Meeting
October 14, 2014 11:46 ET
|
Oxurion NV
On-going ORBIT and OZONE real-world data studies with JETREA® progressing as planned Leuven, October 14, 2014 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company...
ThromboGenics' JETREA® Gains Approval in South Korea
September 08, 2014 01:47 ET
|
Oxurion NV
Leuven, September 8, 2014 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today...
ThromboGenics Business Update H1 2014
August 28, 2014 11:42 ET
|
Oxurion NV
REGULATED INFORMATION Financial Revenues of €7.1 million in the first half of 2014, compared with €102.7 million in the same period in 2013 (including €90 million in milestone payments) Gross...
ThromboGenics' JETREA Receives Positive Recommendation from Scottish Medicines Consortium (SMC)
August 11, 2014 11:47 ET
|
Oxurion NV
Leuven, August 11, 2014 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today...
ThromboGenics' JETREA Nominated for 2014 Prix Galien USA
July 31, 2014 10:20 ET
|
Oxurion NV
Leuven, Belgium - 31 July, 2014 - ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today...
ThromboGenics Provides Update on Strategic Review Process
June 24, 2014 02:05 ET
|
Oxurion NV
Company to Remain Independent CFO and Board Member Chris Buyse to Resign Leuven, Belgium - June 24, 2014 - In response to market rumors, ThromboGenics NV (Euronext Brussels: THR) today issues an...
ThromboGenics Business Update
May 22, 2014 11:44 ET
|
Oxurion NV
REGULATED INFORMATION ThromboGenics Business Update Corporate In February, the Board of Directors of ThromboGenics decided to explore strategic options for the Company. This decision is...
ThromboGenics Activates 50th Retina Center for its US Observational Patient Trial with JETREA® (ORBIT)
April 29, 2014 01:35 ET
|
Oxurion NV
Quick activation rate underwrites strong commitment by the US Retina Community to help provide further insight and support in the use of JETREA® for the treatment of symptomatic vitreomacular...